Business Context and Reporting Period
This Form 8-K Current Report was filed by AnaptysBio, Inc. on July 20, 2020. The filing primarily addresses Item 5.02, reporting the appointment of a new executive officer and the associated compensatory arrangements.
Key Appointment
The Board of Directors appointed Paul F. Lizzul, M.D., Ph.D., M.P.H., M.B.A., as Chief Medical Officer, effective July 31, 2020. Dr. Lizzul brings prior experience as Executive Medical Director at Amgen Inc. and Chief Medical Officer at Sienna Biopharmaceuticals, Inc.
Financial Metrics and Compensation
This filing does not contain general financial performance metrics such as revenue, profit, cash flow, or debt levels. The only financial data provided relates to the specific employment agreement for the new Chief Medical Officer:
- Base Salary: $400,000 annually.
- Target Cash Bonus: Up to 40% of base salary, contingent on performance goals.
- Sign-on Bonus: $100,000, vesting monthly over 24 months (with clawback provisions for termination for cause).
- Equity Grant: Option to purchase 90,000 shares of common stock, vesting 25% on the first anniversary and monthly thereafter for 36 months.
- Severance: Nine months of salary and COBRA premiums for termination without cause; twelve months and full option vesting in the event of a change in control followed by termination without cause.
Material Changes
The material change reported is the addition of Dr. Lizzul to the executive leadership team. There are no reported changes to the company's capital structure, debt, or operational status in this document.
Outlook, Risks, and Contingencies
The filing does not provide updated business guidance, outlook, or general risk factors. The primary contingency noted is the "change in control" provision within Dr. Lizzul's employment agreement, which accelerates equity vesting and extends severance benefits if a change in control occurs within 13 months of the event.
Investor Verification Checklist
- Verify the effective date of Dr. Lizzul's appointment (July 31, 2020) against the press release filed as Exhibit 99.01.
- Review the vesting schedule for the 90,000 stock options granted to ensure alignment with the 4-year vesting timeline described.
- Confirm the company's current cash position to assess the impact of the $100,000 sign-on bonus and future salary obligations, as this filing does not disclose current liquidity.
- Check for any subsequent filings regarding the performance goals tied to the 40% target bonus.